SCHEDULE: Federated Hermes Reduces IDEAYA Biosciences Stake

Federated Hermes, Inc. and affiliated entities have reported a reduced beneficial ownership in IDEAYA Biosciences, Inc. to 3.87% of common stock.

Summary

• Federated Hermes, Inc. and its affiliates, including the Voting Shares Irrevocable Trust and the Donahue family, reported beneficial ownership of 3,395,771 shares of IDEAYA Biosciences, Inc. common stock.
• This represents 3.87% of the class of securities, indicating a reduction from a previous filing where they held over 5%.
• The filing is an Amendment No. 3 to a Schedule 13G, signifying an update to their ownership position.
• The reporting persons disclaim beneficial ownership of the securities held by the Managed Funds, stating the report should not be construed as an admission of such ownership.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by Federated Hermes and its affiliates to below 5%, which could be interpreted as a negative signal by the market regarding IDEAYA Biosciences. However, the filing explicitly states the investment is passive and not intended to influence control, suggesting it may be part of routine portfolio adjustments.

Positives

• The filing indicates a passive investment stance, with no intent to influence control, which can reduce uncertainty for the company's management.
• The reduction in stake could free up capital for Federated Hermes for other investments, reflecting active portfolio management.

Negatives

• A reduction in stake by a significant institutional investor like Federated Hermes could be perceived negatively by the market, potentially signaling a lack of conviction or a re-evaluation of the investment.
• The decrease below the 5% threshold means Federated Hermes is no longer a major beneficial owner requiring regular 13G filings, reducing transparency on their future holdings unless they cross 5% again.

Risks

• The market might interpret the reduction in ownership by Federated Hermes as a negative signal regarding IDEAYA Biosciences' future prospects or valuation.
• A large institutional investor reducing its stake could put downward pressure on the stock price if the market reacts unfavorably.

Future Outlook

This filing does not contain any forward-looking statements or guidance from IDEAYA Biosciences, Inc. as it pertains solely to the beneficial ownership position of Federated Hermes, Inc. and its affiliates.

Management Comments

• In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects a change in an institutional investor's position in a biotechnology company. Such changes are common in the highly dynamic biotech sector, where investment theses can evolve rapidly based on clinical trial results, regulatory approvals, and market conditions. A reduction in stake by a major asset manager like Federated Hermes could be part of a broader portfolio rebalancing or a specific re-evaluation of IDEAYA Biosciences within the competitive biotech landscape.

Comparison to Industry Standards

• Institutional investors frequently adjust their holdings in public companies, especially in sectors like biotechnology which are subject to high volatility and specific catalysts.
• A reduction below the 5% threshold is a standard event that triggers an amendment to a Schedule 13G, indicating a passive investor is no longer required to report their holdings as frequently.
• The disclaimer of beneficial ownership for managed funds is a common practice for large asset managers to clarify their role as investment advisers rather than direct owners.

Stakeholder Impact

• Shareholders: May react negatively to the news of a major institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• Management: May need to address market concerns if the reduction in ownership is perceived as a lack of confidence in the company's strategy or prospects.

Next Steps

• Federated Hermes and its affiliates will no longer be required to file Schedule 13G amendments unless their beneficial ownership again exceeds 5% of IDEAYA Biosciences' common stock.

Key Dates

Recommendation

The reduction of beneficial ownership by Federated Hermes and its affiliates to below 5% suggests a potential decrease in confidence or a strategic shift away from IDEAYA Biosciences. For a seasoned investor, this move by a large institutional player could be a signal to re-evaluate their own position, potentially leading to a 'sell' recommendation if the underlying reasons for Federated Hermes's divestment are perceived as fundamental weaknesses or if the market reacts negatively to the news.

Keywords

IDEAYA Biosciences, Federated Hermes, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, SEC filing, investment management